Skip to Content

New Additions to Drugs.com for 2013

We update the Drugs.com database on a regular cycle. The following new drug information was added in 2013:

Orenitram
Dec 30, 2013 - Orenitram (treprostinil extended-release) is an oral prostacyclin for the treatment of pulmonary arterial hypertension.

Anoro Ellipta
Dec 18, 2013 - Anoro Ellipta (umeclidinium bromide and vilanterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) combination for the treatment of COPD.

Sovaldi
Dec 6, 2013 - Sovaldi (sofosbuvir) is a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.

Velphoro
Nov 30, 2013 - Velphoro (sucroferric oxyhydroxide) is a chewable, iron-based phosphate binder for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis.

Olysio
Nov 26, 2013 - Olysio (simeprevir) is a protease inhibitor for the treatment of chronic hepatitis C virus infection.

Luzu
Nov 17, 2013 - Luzu (luliconazole) Cream is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis.

Imbruvica
Nov 13, 2013 - Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease.

Aptiom
Nov 13, 2013 - Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures.

Gazyva
Nov 6, 2013 - Gazyva (obinutuzumab) is a CD20-directed cytolytic antibody indicated, in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Vizamyl
Oct 30, 2013 - Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders.

Zohydro ER
Oct 26, 2013 - Zohydro ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.

Opsumit
Oct 20, 2013 - Opsumit (macitentan) is a dual endothelin receptor antagonist for the treatment of patients with pulmonary arterial hypertension.

Adempas
Oct 9, 2013 - Adempas (riociguat) is an oral soluble guanylate cyclase (sGC) stimulator for the treatment of pulmonary hypertension.

Duavee
Oct 3, 2013 - Duavee (bazedoxifene and conjugated estrogens) is an estrogen agonist/antagonist and conjugated estrogens combination indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal osteoporosis in women with an intact uterus.

Mirvaso
Aug 27, 2013 - Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema of rosacea.

Valchlor
Aug 27, 2013 - Valchlor (mechlorethamine) gel an alkylating agent indicated for the topical treatment of Stage IA and IB mycosis fungoides‐type cutaneous T‐cell lymphoma.

Tivicay
Aug 12, 2013 - Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.

Fetzima
Jul 31, 2013 - Fetzima (levomilnacipran) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.

Injectafer
Jul 28, 2013 - Injectafer (ferric carboxymaltose) is an iron replacement product indicated for the treatment of iron deficiency anemia.

Gilotrif
Jul 12, 2013 - Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Zubsolv
Jul 8, 2013 - Zubsolv (buprenorphine and naloxone) is a sublingual partial opioid agonist indicated for the maintenance treatment of opioid dependence.

Brisdelle
Jun 30, 2013 - Brisdelle (paroxetine mesylate) is a low-dose selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Mekinist
May 31, 2013 - Mekinist (trametinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. It is also used in combination with dabrafenib for the treatment of non-small cell lung cancer and thyroid cancer.

Tafinlar
May 30, 2013 - Tafinlar (dabrafenib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. It is also used in combination with trametinib for the treatment of non-small cell lung cancer and thyroid cancer.

Xofigo
May 29, 2013 - Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer.

Breo Ellipta
May 10, 2013 - Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.

Suvorexant
May 9, 2013 - Suvorexant is a potential new insomnia drug which appears to help people fall asleep without causing next-day drowsiness.

Liptruzet
May 6, 2013 - Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.

Procysbi
May 2, 2013 - Procysbi (cysteamine bitartrate) is a cystine depleting agent indicated for the treatment of nephropathic cystinosis.

Kcentra
Apr 30, 2013 - Kcentra (prothrombin complex concentrate, human) is a plasma-derived product indicated for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding.

Simbrinza
Apr 24, 2013 - Simbrinza (brimonidine and brinzolamide) is a fixed combination of an alpha 2 adrenergic receptor agonist and a carbonic anhydrase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Sitavig
Apr 21, 2013 - Sitavig (acyclovir) is a mucoadhesive buccal tablet formulation of the antiviral drug acyclovir indicated for the treatment of recurrent orofacial herpes (cold sores).

Diclegis
Apr 9, 2013 - Diclegis (doxylamine and pyridoxine) is an antihistamine and vitamin B6 analog combination indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Dotarem
Mar 30, 2013 - Dotarem (gadoterate meglumine) is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI).

Invokana
Mar 30, 2013 - Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, for reducing the risk of cardiovascular events in patients with type 2 diabetes and CV disease, and reducing the risk of end-stage kidney disease and cardiovascular events in patients with type 2 diabetes and diabetic kidney disease.

Tecfidera
Mar 27, 2013 - Tecfidera (dimethyl fumarate) is an oral Nrf2 pathway activator for the treatment of relapsing forms of multiple sclerosis.

Kadcyla
Feb 26, 2013 - Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive breast cancer.

Osphena
Feb 26, 2013 - Osphena (ospemifene) is an estrogen agonist/antagonist indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause.

Pomalyst
Feb 8, 2013 - Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma and AIDS-related Kaposi sarcoma.

Ravicti
Feb 6, 2013 - Ravicti (glycerol phenylbutyrate) is a nitrogen-binding agent for the chronic management of patients with urea cycle disorders.

Kynamro
Jan 30, 2013 - Kynamro (mipomersen) is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated for the treatment of patients with homozygous familial hypercholesterolemia.

Kazano
Jan 30, 2013 - Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.

Oseni
Jan 30, 2013 - Oseni (alogliptin and pioglitazone) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and thiazolidinedione fixed-dose combination for the treatment of type 2 diabetes.

Nesina
Jan 28, 2013 - Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.

Zecuity
Jan 23, 2013 - Zecuity (sumatriptan iontophoretic transdermal system) is a serotonin (5HT) 1b/1d receptor agonist (triptan) indicated for the acute treatment of migraine.

Octaplas
Jan 23, 2013 - Octaplas is a solvent/detergent (S/D) treated, pooled human plasma indicated for the replacement of multiple coagulation factors in patients with acquired deficiencies and plasma exchange in patients with thrombotic thrombocytopenic purpura.

Uceris
Jan 16, 2013 - Uceris (budesonide) is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.

Skyla
Jan 10, 2013 - Skyla (levonorgestrel) is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to three years.

Fulyzaq
Jan 2, 2013 - Fulyzaq (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy.

Browse additions by year: